Underlying mechanisms of pharmacology and toxicity of a novel PPAR agonist revealed using rodent and canine hepatocytes.

@article{Guo2007UnderlyingMO,
  title={Underlying mechanisms of pharmacology and toxicity of a novel PPAR agonist revealed using rodent and canine hepatocytes.},
  author={Yin Guo and Robert A. Jolly and Bartley W. Halstead and Thomas K. Baker and John P Stutz and Melanie Huffman and John N. Calley and Adam West and Hong Qing Gao and George H. Searfoss and Shuyu Dan Li and Armando R. Irizarry and Hui-Rong Qian and James L. Stevens and Timothy P. Ryan},
  journal={Toxicological sciences : an official journal of the Society of Toxicology},
  year={2007},
  volume={96 2},
  pages={
          294-309
        }
}
  • Yin Guo, R. Jolly, T. Ryan
  • Published 1 April 2007
  • Biology, Medicine
  • Toxicological sciences : an official journal of the Society of Toxicology
Marked species-specific responses to agonists of the peroxisome proliferator-activated alpha receptor (PPAR alpha) have been observed in rats and dogs, two species typically used to assess the potential human risk of pharmaceuticals in development. In this study, we used primary cultured rat and dog hepatocytes to investigate the underlying mechanisms of a novel PPAR alpha and -gamma coagonist, LY465608, relative to fenofibrate, a prototypical PPAR alpha agonist. As expected, rat hepatocytes… 

Figures and Tables from this paper

Exposure to perfluorooctane sulfonate or fenofibrate causes PPAR-alpha dependent transcriptional responses in chicken embryo hepatocytes.

Inhibitory role of peroxisome proliferator‐activated receptor gamma in hepatocarcinogenesis in mice and in vitro

TLDR
Loss of one PPARγ allele is sufficient to enhance susceptibility to HCC and suppresses tumor cell growth through reducing cell proliferation and inducing G2/M phase arrest, apoptosis, and up‐regulating growth differentiation factor‐15, which acts as a tumor‐suppressor gene in the liver.

Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-γ and PPAR-α agonists on carbohydrate and lipid metabolism in db/db and diet-induced obese mice

TLDR
This is the first report of a synergistic glucose- and lipid-lowering effect of BVC and synthetic agonists induced by unique binding with PPAR-γ or -α, which may improve the efficacy and decrease the toxicity of marketed drugs for use as adjunctive therapy to treat the metabolic syndrome.

Administration of Fenofibrate Markedly Elevates Fabp3 in Rat Liver and Plasma and Confounds Its Use as a Preclinical Biomarker of Cardiac and Muscle Toxicity.

TLDR
It is shown that fenofibrate induces liver mRNA levels of Fabp3 ~5000-fold resulting in an approximately 50-fold increase in FABP3 protein levels in the whole liver, which complicates the interpretation and potential use of FABp3 as a specific biomarker for PPARα-induced muscle toxicities.

Peroxisome Proliferator-Activated Receptor Alpha Target Genes

TLDR
An overview of the involvement of PPARα in lipid metabolism and other pathways through a detailed analysis of the different known or putative PPAR α target genes is presented.

BEYOND PEROXISOME: ABCD2 MODIFIES PPARα SIGNALING AND IDENTIFIES A SUBCLASS OF PEROXISOMES IN MOUSE ADIPOSE TISSUE

TLDR
It is concluded that D2 can modulate genomic responses to fibrates, but that these effects are not sufficiently robust to alter the effects of fibrate treatment on diet-induced obesity phenotypes.

Effects of 18 perfluoroalkyl compounds on mRNA expression in chicken embryo hepatocyte cultures.

TLDR
This study is the first to expose CEH cultures to multiple PFCs in vitro and demonstrates that exposure to PFC solutions of different isomeric content or chain length causes variable transcriptional responses.

Peroxisome Proliferator-Activated Receptor Activation in Precision-Cut Bovine Liver Slices Reveals Novel Putative PPAR Targets in Periparturient Dairy Cows

Metabolic challenges experienced by dairy cows during the transition between pregnancy and lactation (also known as peripartum), are of considerable interest from a nutrigenomic perspective. The

References

SHOWING 1-10 OF 64 REFERENCES

Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes.

TLDR
The results showed that human hepatocytes limit the extent of peroxisome proliferation regardless of PPARalpha expression, and confirmed that PPAR alpha and PPREs are important determinants for the species-specificity ofperoxisomes proliferation.

Diminished Hepatocellular Proliferation in Mice Humanized for the Nuclear Receptor Peroxisome Proliferator-Activated Receptor α

TLDR
It is established that following ligand activation, the PPARα-mediated pathways controlling lipid metabolism are independent from those controlling the cell proliferation pathways and suggested that structural differences between human and mouse PPAR α are responsible for the differential susceptibility to the development of hepatocarcinomas observed after treatment with fibrates.

PPARalpha agonist-induced rodent tumors: modes of action and human relevance.

TLDR
An in-depth analysis of the state of the science on several topics critical to evaluating the relationship between the MOA for PPARalpha agonists and the human relevance of related animal tumors is provided.

Differential Gene Regulation in Human Versus Rodent Hepatocytes by Peroxisome Proliferator-activated Receptor (PPAR) α

TLDR
The results suggest that other factors besides PPARα levels determine the species-specific response of human and rat hepatocytes to the induction of PP.

PPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance

TLDR
An in-depth analysis of the state of the science on several topics critical to evaluating the relationship between the MOA for PPARα agonists and the human relevance of related animal tumors produces a range of outcomes, depending partly on the quality and quantity of MOA data available from laboratory animals and related information from human data sources.

Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?

TLDR
It is now established that the species difference between rodents and humans in response to peroxisome proliferators is due in part to PPAR alpha, and future research directions that should be taken to delineate the mechanisms underlying PPARalpha agonist-induced hepatocarcinogenesis are identified.

Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis.

TLDR
Structural differences between human and mouse PPARalpha are suggested to be responsible for the differential susceptibility to the peroxisome proliferator-induced hepatocarcinogenesis of hPPARalpha mice.

Peroxisome proliferator-activated receptor-α and liver cancer: where do we stand?

TLDR
It is now established that the species difference between rodents and humans in response to peroxisome proliferators is due in part to PPAR α, and future research directions that should be taken to delineate the mechanisms underlying PPARα agonist-induced hepatocarcinogenesis are identified.
...